HK1202157A1 - Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment - Google Patents
Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment Download PDFInfo
- Publication number
- HK1202157A1 HK1202157A1 HK15102644.9A HK15102644A HK1202157A1 HK 1202157 A1 HK1202157 A1 HK 1202157A1 HK 15102644 A HK15102644 A HK 15102644A HK 1202157 A1 HK1202157 A1 HK 1202157A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- prediction
- coronary artery
- artery disease
- disease patients
- predicting
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161556909P | 2011-11-08 | 2011-11-08 | |
| EP11188328.6A EP2592423A1 (en) | 2011-11-08 | 2011-11-08 | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
| EP11188328.6 | 2011-11-08 | ||
| US61/556909 | 2011-11-08 | ||
| PCT/EP2012/071972 WO2013068373A2 (en) | 2011-11-08 | 2012-11-07 | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1202157A1 true HK1202157A1 (en) | 2015-09-18 |
Family
ID=45033777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15102644.9A HK1202157A1 (en) | 2011-11-08 | 2012-11-07 | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9052328B2 (https=) |
| EP (3) | EP2592423A1 (https=) |
| JP (1) | JP6388283B2 (https=) |
| CN (1) | CN103917876B (https=) |
| CA (1) | CA2853220A1 (https=) |
| HK (1) | HK1202157A1 (https=) |
| WO (1) | WO2013068373A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2592423A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
| EP2592422A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
| ES2552371T3 (es) * | 2012-05-25 | 2015-11-27 | Zora Biosciences Oy | Biomarcadores sensibles, eficaces e inocuos, para la inhibición de la Proproteína Convertasa Subtilisina/Kexina de tipo 9 (PCSK9) |
| CA2926592A1 (en) * | 2013-11-14 | 2015-05-21 | Nestec S.A. | Lipid biomarkers of healthy ageing |
| CN106457090B (zh) | 2014-04-10 | 2020-09-29 | Mep马解决方案有限责任公司 | 粪便中寄生虫卵的定量方法 |
| US9347960B2 (en) | 2014-06-16 | 2016-05-24 | Zora Biosciences, Oy | Ceramides and their use in diagnosing CVD |
| US9952232B2 (en) | 2014-09-11 | 2018-04-24 | Liposcience, Inc. | Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter |
| WO2016100549A2 (en) | 2014-12-16 | 2016-06-23 | Washington University | Ceramides for evaluating risk of cardiovascular disease |
| US20180238914A1 (en) * | 2015-08-19 | 2018-08-23 | Metanomics Gmbh | Means and methods for diagnosing cardiac disease in a subject |
| JP6830899B2 (ja) * | 2015-10-20 | 2021-02-17 | メディミューン，エルエルシー | 冠動脈疾患の診断マーカー |
| US10184932B2 (en) | 2015-12-07 | 2019-01-22 | Zora Biosciences Oy | Use of ceramides and LPLs in diagnosing CVD |
| CN105424841B (zh) * | 2015-12-25 | 2017-11-03 | 齐炼文 | 用于诊断冠状动脉粥样硬化的代谢标志物 |
| CN107014942A (zh) * | 2017-05-05 | 2017-08-04 | 北京骐骥生物技术有限公司 | 利用脂质生物标志物预测糖尿病冠心病的方法 |
| CN107144624B (zh) * | 2017-05-15 | 2021-01-05 | 中国科学院生态环境研究中心 | 甄别二氧化硅颗粒来源的方法 |
| CN108037275A (zh) * | 2017-12-14 | 2018-05-15 | 北京豪思生物科技有限公司 | 一种用于评估冠状动脉疾病的试剂盒 |
| WO2019119049A1 (en) * | 2017-12-20 | 2019-06-27 | Baker Heart and Diabetes Institute | Method of predicting drug therapeutic responder status and methods of treatment |
| CA3122035A1 (en) * | 2018-12-06 | 2020-06-11 | Zora Biosciences Oy | Biomarkers for cardiovascular events |
| CN113533754A (zh) * | 2021-07-12 | 2021-10-22 | 北京市心肺血管疾病研究所 | 神经酰胺在制备用于评估高血压患者发生不良事件风险的试剂盒中的应用 |
| AU2024240838A1 (en) * | 2023-03-20 | 2025-11-06 | Baker Heart and Diabetes Institute | Methods of assessing metabolic health |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2293718A1 (en) * | 1997-06-10 | 1998-12-17 | Medlyte Diagnostics, Inc. | Methods for early detection of heart disease |
| WO2004038381A2 (en) | 2002-10-25 | 2004-05-06 | Metabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| GB0517878D0 (en) * | 2005-09-02 | 2005-10-12 | Bioinvent Int Ab | Immunotherapeutic treatment |
| US7972802B2 (en) | 2005-10-31 | 2011-07-05 | University Of Washington | Lipoprotein-associated markers for cardiovascular disease |
| US8137977B2 (en) * | 2006-04-24 | 2012-03-20 | Children's Hospital & Research Center At Oakland | Lipidomic approaches to determining drug response phenotypes in cardiovascular disease |
| DE102006034153B4 (de) | 2006-07-24 | 2018-02-08 | Magna powertrain gmbh & co kg | Getriebe |
| US20100179066A1 (en) | 2007-06-07 | 2010-07-15 | Inserm (Institut National De La Santé Et De La Rec | Method for Assessing the Risk of a Cardiovascular Disease and for Diagnosing Dyslipidemia |
| BRPI0812412B1 (pt) * | 2007-06-08 | 2018-12-18 | Quest Diagnostics Investments Incorporated | processos para purificação de lipoproteínas adequadas para a análise da mobilidade diferencial de partículas carregadas da classe ou da subclasse das lipoproteínas, para obtenção de lp(a) purificado, para purificação de lipoproteínas para a análise da mobilidade diferencial de partículas carregadas, o dito processo não incluindo a centrifugação |
| EP2048243A1 (en) | 2007-09-24 | 2009-04-15 | sanofi-aventis | Use of clec1B for the determination of cardiovascular and thrombotic risk |
| WO2009096903A1 (en) | 2008-01-28 | 2009-08-06 | National University Of Singapore | Lipid tumour profile |
| EP2265642A4 (en) | 2008-03-12 | 2012-05-02 | Otago Innovation Ltd | BIOMARKERS |
| CA2741117A1 (en) | 2008-10-30 | 2010-05-06 | Centre De Recherche Public De La Sante | Biomarkers for heart failure |
| US20110034419A1 (en) * | 2009-06-27 | 2011-02-10 | Musc Foundation For Research Development | Cardioprotective Drugs and Diagnostics for Assessing Risk of Cardiovascular Disease |
| JP5739898B2 (ja) * | 2009-11-17 | 2015-06-24 | ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | 心疾患マーカーとしての尿中トリアオシルセラミド（ｇｂ３） |
| AU2010324544A1 (en) | 2009-11-27 | 2012-06-21 | Baker Idi Heart And Diabetes Institute Holdings Limited | Lipid biomarkers for stable and unstable heart disease |
| NO2385374T3 (https=) | 2010-05-05 | 2014-06-07 | ||
| CN103154742B (zh) | 2010-06-20 | 2017-11-21 | 佐拉生物科学公司 | 用于鉴定高风险冠状动脉疾病患者的脂质组学标志 |
| JP5980900B2 (ja) | 2011-04-08 | 2016-08-31 | ゾラ バイオサイエンシーズ オサケ ユキチュア | スタチン誘発性筋毒性の高感度検出のためのバイオマーカー |
| EP2592422A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
| EP2592423A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
-
2011
- 2011-11-08 EP EP11188328.6A patent/EP2592423A1/en not_active Withdrawn
-
2012
- 2012-11-07 CN CN201280054323.8A patent/CN103917876B/zh active Active
- 2012-11-07 WO PCT/EP2012/071972 patent/WO2013068373A2/en not_active Ceased
- 2012-11-07 US US14/356,594 patent/US9052328B2/en active Active
- 2012-11-07 EP EP12781324.4A patent/EP2776841B1/en active Active
- 2012-11-07 EP EP17150693.4A patent/EP3208617B1/en active Active
- 2012-11-07 HK HK15102644.9A patent/HK1202157A1/xx unknown
- 2012-11-07 JP JP2014540426A patent/JP6388283B2/ja active Active
- 2012-11-07 CA CA2853220A patent/CA2853220A1/en not_active Abandoned
-
2015
- 2015-05-27 US US14/722,964 patent/US9423406B2/en active Active
-
2016
- 2016-07-14 US US15/210,048 patent/US9863965B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3208617A2 (en) | 2017-08-23 |
| EP3208617B1 (en) | 2021-02-24 |
| CA2853220A1 (en) | 2013-05-16 |
| JP2014532885A (ja) | 2014-12-08 |
| EP3208617A3 (en) | 2017-11-01 |
| US9423406B2 (en) | 2016-08-23 |
| US9863965B2 (en) | 2018-01-09 |
| US20150260737A1 (en) | 2015-09-17 |
| EP2592423A1 (en) | 2013-05-15 |
| CN103917876A (zh) | 2014-07-09 |
| JP6388283B2 (ja) | 2018-09-12 |
| EP2776841A2 (en) | 2014-09-17 |
| WO2013068373A3 (en) | 2013-07-18 |
| US20140295467A1 (en) | 2014-10-02 |
| US9052328B2 (en) | 2015-06-09 |
| WO2013068373A2 (en) | 2013-05-16 |
| EP2776841B1 (en) | 2017-01-11 |
| CN103917876B (zh) | 2018-02-02 |
| US20160320418A1 (en) | 2016-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1202154A1 (en) | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment | |
| HK1202157A1 (en) | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment | |
| WO2011161062A3 (en) | Lipidomic biomarkers for identification of high-risk coronary artery disease patients | |
| NZ602056A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| WO2012177945A3 (en) | Diagnostic methods for eosinophilic esophagitis | |
| NZ597273A (en) | Trimethylamine-containing compounds for diagnosis and prediction of disease | |
| WO2014037588A3 (en) | Methods and compounds for preventing, treating and diagnosing an inflammatory condition | |
| WO2013190075A3 (en) | Specific biomarkers for hepatocellular carcinoma (hcc) | |
| WO2012174282A3 (en) | Biomarker compositions and methods | |
| WO2009077864A3 (en) | Compositions and methods of detecting tiabs | |
| WO2011015944A3 (en) | Use of free dna as an early predictor of severity in acute pancreatitis | |
| WO2007117444A3 (en) | Protein detection by aptamers | |
| ECSP088081A (es) | Detección de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapéutico correspondiente | |
| NZ609824A (en) | Immunochromatography devices, methods and kits | |
| Leung et al. | Ovarian cancer biomarkers: current state and future implications from high-throughput technologies | |
| WO2009019367A3 (fr) | Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal | |
| EP2569635A4 (en) | METHOD FOR DIAGNOSIS AND / OR TREATMENT OF ENZEPHALITIS OR EPILEPSY | |
| WO2014053996A3 (en) | Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs | |
| WO2012050365A3 (ko) | 교모세포종의 진단 또는 예후 예측용 바이오 마커 및 그 용도 | |
| WO2015077382A3 (en) | Combined cytology and molecular testing for early detection of esophageal adenocarcinoma | |
| EP2668288A2 (en) | Complex mirna sets as novel biomarkers for lung diseases | |
| WO2009099561A3 (en) | Urinary ca125 peptides as biomarkers of ovarian cancer | |
| EP2415877A3 (en) | Means and methods for diagnosing pancreatic cancer | |
| WO2013167727A3 (en) | Method for determining arthritis relapse risk | |
| FI3356826T3 (fi) | Gdf-15 melanooman diagnostisena markkerina |